Publications
- Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial2015 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes2015 | First Faculty of Medicine, Third Faculty of Medicine
- Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer2015 | Second Faculty of Medicine
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study2015 | First Faculty of Medicine
- VEGFREverolimus in the treatment of metastatic renal cell carcinoma - subanalysis of patients from the RECORD-1 study pretreated with one vs. two VEGFR inhibitors2012 | Second Faculty of Medicine
- Low Molecular Weight Heparins for Thromboprophylaxis during Induction Chemotherapy in Patients with Multiple Myeloma2011 | Publication without faculty affiliation
- Kidney cancer. What is the next step after failure of treatment with angiogenesis inhibitors?2010 | Second Faculty of Medicine
- Integrative analysis of mRNA and miRNA expression profiles and somatic variants in oxysterol signaling in early-stage luminal breast cancer2023 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen
- Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States2023 | Faculty of Social Sciences
Loading network view...